Lenazine

Quick links to important sections

Lenazine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lenazine

Lenazine is a prescription medicine identified by its active component, Promethazine hydrochloride, and is fundamentally classified as a first-generation antihistamine.

Property Description
Active ingredient Promethazine hydrochloride
Form Tablets, Syrup, Injectable Solution, Suppositories
Pharmacological class First-generation Antihistamine
General Purpose Symptomatic relief of allergic conditions and sedation
Origin Synthetic drug, Phenothiazine derivative

What Type of Medicine is Lenazine?

Lenazine is a single-ingredient product whose active constituent, Promethazine hydrochloride, is chemically categorized as a phenothiazine derivative and a synthetic drug. This classification is significant because this particular type of antihistamine is clinically recognized for its capacity to readily affect the central nervous system, a characteristic widely documented in pharmacological studies.

Composition and General Purpose of Promethazine

The drug's core action is defined by its strong Histamine H1 receptor blockade, which prevents histamine from binding and thus helps to alleviate the physical manifestations of an allergic response. In addition to this primary function, the compound exhibits significant anticholinergic activity and is well-known for its pronounced central nervous system depression, acting as a clinically useful sedative. Reviewing its established profile confirms its therapeutic efficacy in inducing sleep and addressing motion sickness symptoms. This multi-receptor activity determines its general purpose: providing relief for symptoms associated with allergic conditions, facilitating sedation and quiet restfulness, and helping to manage feelings of nausea and motion sickness.

Available Preparations and Identity Forms

Lenazine is produced in various pharmaceutical preparations, enabling multiple routes of delivery. These high-level dosage forms include solid tablets, liquid preparations such as oral solution or syrup, a sterile injectable solution for parenteral administration, and forms designated for rectal administration as suppositories. This availability across different forms is a defining characteristic of the drug entity, providing versatility in how the medication can be supplied across various clinical needs.

Regulatory References

  1. Promethazine Hydrochloride Tablets, USP (12.5 mg, 25 mg and 50 mg) Rx only
  2. Antihistamines - StatPearls - NCBI Bookshelf
  3. Anticholinergic Medications - StatPearls - NCBI Bookshelf
  4. Promethazine Hydrochloride Tablets, USP (12.5 mg, 25 mg and 50 mg) Rx only - DailyMed
  5. Procedural Sedation - StatPearls - NCBI Bookshelf
  6. Nausea and Vomiting - Clinical Methods - NCBI Bookshelf
  7. Promethazine: MedlinePlus Drug Information
  8. Definition of suppository - NCI Dictionary of Cancer Terms

What side effects are possible with Lenazine?

Possible Side Effects and Safety Information

The safety profile of Lenazine, containing Promethazine hydrochloride, is officially classified based on the effects associated with its action as a first-generation antihistamine and phenothiazine derivative. The profile includes adverse reactions organized by frequency and the body systems affected, according to regulatory documents from health authorities.

Common and Expected Adverse Reactions

The most frequently documented side effects are those related to Central Nervous System (CNS) depression and anticholinergic activity. These effects, often classified as Common or Very Common in official labeling, include drowsiness, sedation, dizziness, and impaired mental alertness. Other frequent effects are dry mouth, blurred vision, and urinary retention.

Serious Adverse Reactions and Systemic Concerns

Official prescribing information documents list the potential for rare but serious adverse reactions. These include events such as seizures and Neuroleptic Malignant Syndrome (NMS). Additionally, the label documents the potential for certain severe blood dyscrasias, such as agranulocytosis and leukopenia, which are classified under Blood and Lymphatic System Disorders.

Population-Specific Safety Statements

Regulatory safety constraints explicitly note that the medicine is generally restricted or contraindicated in children younger than two years due to a documented risk of fatal respiratory depression. In older adults (geriatric patients), official documents indicate an increased susceptibility to both the sedative effects and the anticholinergic adverse reactions, such as confusion and disorientation.

Contextual Safety Patterns

The official safety information notes that drowsiness is often most pronounced during the first days of treatment, with the possibility of tolerance developing to the sedating effects over time. The drug may also impair the physical and mental abilities required for operating machinery, a high-level safety consideration included in official documentation.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Lenazine (Promethazine hydrochloride) overdose presents with serious central nervous system (CNS) and cardiovascular manifestations documented in regulatory labeling. The presentation may range from profound CNS depression, including somnolence and coma, to paradoxical effects such as excitation, hallucinations, restlessness, and convulsive seizures. Other documented signs of toxicity include tachycardia (rapid heartbeat), fluctuations in blood pressure, and the appearance of extrapyramidal symptoms. Anticholinergic signs, such as dry mouth and dilated pupils, are also documented.

The most severe outcomes officially documented include fatal respiratory depression and sudden death, especially associated with excessively large dosages in pediatric patients. The potentially fatal complication Neuroleptic Malignant Syndrome (NMS) is also reported in association with promethazine.

Required Emergency Actions

Urgent medical attention must be sought immediately for any suspected overdose. Emergency services should be contacted if the individual has collapsed, experienced a seizure, or has trouble breathing or cannot be awakened. Management involves intensive symptomatic and supportive treatment, including medical monitoring of vital signs (pulse, breathing, blood pressure) and ECG (heart tracing). The official prescribing information notes that Epinephrine should not be used to treat associated hypotension. The medication is contraindicated in pediatric patients less than two years of age due to the high risk of fatal respiratory depression.

Therapeutic Uses of Lenazine

Lenazine is commonly used across conditions presenting with acute episodes and is applied across domains where additional symptomatic support is needed, addressing diverse symptoms related to physical discomfort and heightened physiological activity.

This medication is commonly used to help with the symptomatic management of allergic reactions, including hives and allergic rhinitis; for the control and prevention of nausea and vomiting; and for **situational sedation.


Managing Acute Symptoms and Promoting Rest

The medication helps address symptom clusters that may become intense or disruptive, such as the itching, sneezing, and discomfort associated with allergies, or the challenging symptoms linked to motion sickness. It is applied in situations involving certain distressing symptoms, and is relevant for easing symptoms in clinical settings that involve acute or unstable symptom patterns, such as before and after surgical procedures or during episodes of acute short-term insomnia.

“It provides support that helps ease the overall symptom burden, which is relevant in contexts marked by increased discomfort or tension.”

Quick Fact: Relief for Nausea and Allergic Itching

Lenazine offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, assists with maintaining functional stability by supporting the patient's ability to achieve rest when needed.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Lenazine

Regulatory documents establish strict limits on who can use Lenazine, a medicine containing a combination of codeine, ephedrine, and promethazine. Eligibility is primarily restricted based on age and specific physiological risk factors.

Lenazine is Contraindicated (Must Not Be Used) for:

Population/Condition Restriction Basis
Children younger than 12 years of age Risk of serious respiratory depression
Adolescents under 18 years post-surgery Following tonsillectomy or adenoidectomy
Individuals who are ultra-rapid metabolizers of codeine Increased risk of life-threatening respiratory events
Patients with significant respiratory depression or acute asthma Risk of exacerbating breathing difficulties
Known hypersensitivity or allergy to any component Risk of severe allergic reaction

Additional Restrictions and Cautions:

  • Pregnancy and Breastfeeding: Use is generally not recommended or should be avoided, as components can pass to the fetus or nursing infant.
  • Elderly Patients: Use requires caution, as older adults may be more sensitive to the medicine's effects.
  • Organ Impairment: Patients with severe hepatic or renal impairment require special consideration and close monitoring.

What should I know about interactions with other medicines?

The official regulatory profile for Lenazine (Promethazine hydrochloride) is characterized by a high potential for pharmacodynamic interactions and specific prohibited combinations, as documented in government labeling.

Interaction Classification Interacting Agents and Outcomes
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs): Co-administration is prohibited due to the risk of intensified anticholinergic and CNS depressant effects. Epinephrine (Adrenaline): Promethazine is documented to reverse the vasopressor effect of this agent.
Pharmacodynamic Augmentation CNS Depressants (e.g., alcohol, opioids, sedatives, tranquilizers): Concurrent use may significantly increase, prolong, or intensify the sedative action and enhance impairment. Anticholinergic Agents: Combining with other drugs that have anticholinergic properties may result in additive effects.
Metabolic Impact Lenazine is identified as a moderate inhibitor of the CYP2D6 enzyme. Co-administration with medicinal products metabolized by this pathway may result in increased plasma concentrations of the co-administered agent.
Administration Constraints Non-absorbed gastrointestinal agents (magnesium, aluminum salts) must not be taken at the same time; a separation of at least 2 hours is required to prevent reduced Lenazine absorption. For pediatric patients (age 2 and older), the use of other respiratory depressant drugs concomitantly must be avoided.

The official interaction data defines a structure focused on preventing additive pharmacological effects and managing exposure changes via CYP2D6 inhibition. Regulatory documents classify these interactions based on severity, ranging from formal prohibitions to required spacing and close monitoring with co-administered substances.

Mechanism of Action

Lenazine's primary pharmacological action is mediated through its principal component, a phenothiazine derivative that acts as a non-selective antagonist across multiple receptor systems, particularly in the central nervous system.

The molecule functions as an inverse agonist at the Histamine H1 receptor, stabilizing the receptor in its inactive state and preventing endogenous histamine from initiating G q-mediated signaling pathways. This action occurs both centrally and peripherally.

Simultaneously, the molecule exhibits antagonist activity at muscarinic acetylcholine receptors M1 – M5, contributing to reduced cholinergic transmission. It also functions as an antagonist at postsynaptic mesolimbic Dopamine D2 receptors and alpha1-adrenergic receptors.

Further, it is established as a non-competitive antagonist of the NMDA receptor complex in the central nervous system. The collective antagonism of H1 and muscarinic receptors alters neuronal excitability, culminating in a systemic reduction of central nervous system activity. The blockade of D2 receptors in the medullary chemoreceptor trigger zone modulates afferent signaling to the vomiting center, affecting efferent parasympathetic output.

Dosage and Administration Information

Official Administration Guidelines

Lenazine (promethazine hydrochloride) is administered through multiple routes, reflecting its use across different clinical needs. The approved forms include oral preparations (tablets and syrup), rectal suppositories, and a sterile injectable solution for parenteral use.


Dosing and Frequency

For adult allergy symptoms, the typical administration pattern is either a single dose of 25 mg taken at bedtime, or a lower dose of 6.25 mg to 12.5 mg taken up to three times daily. When used for the acute treatment of nausea and vomiting, the dose is generally 12.5 mg to 25 mg every four to six hours as needed. Oral forms may be taken with food, water, or milk to help minimize stomach discomfort.


Parenteral Use and Dilution Requirements

The preferred parenteral administration route is deep intramuscular (IM) injection. Intravenous (IV) use is restricted and subject to specific handling requirements. Official instructions mandate that the IV solution must be diluted to a concentration no greater than 1 mg/mL and infused very slowly, at a rate that must not exceed 25 mg per minute, into a large, patent vein.


Population-Specific Parameters

Dosing for pediatric patients aged two years and older must be determined by weight, with a typical dose of approximately 0.5 mg per pound of body weight. The administration of Lenazine is generally not indicated for children under two years of age.

Recent Clinical Evidence

Research evidence / Overview of studies

Research Focus and Design

The trials investigated the drug's intended action as described in the study rationale. The design of the studies focused on the combined use of Drug X and Drug Y.


Observations in Acute Pain

Research evaluated whether the combination of Drug X and Drug Y was associated with changes in acute pain scores over an observed time period.

Study Design Key Observation
Study 1 Randomized, double-blind, placebo-controlled trial A difference in the mean pain intensity scores favoring the combination treatment group compared to placebo at 2, 4, and 6 hours post-dose.
Study 2 Pooled Dose-Response Analysis Higher dosages were generally associated with a greater proportion of participants reporting a 50% or more reduction in pain scores.
  • Conclusion (Study 1): This study concluded that the combination treatment was associated with changes in acute pain.
  • Conclusion (Study 2): The researchers noted a relationship between the varied dosages and the observed change in reported pain scores.

Observations in Migraine

Research explored whether there was an association between the use of Drug Y and the observed time-frame of a migraine event. Research focused on participants using the intervention within one hour of headache onset.

Study Design Key Observation
Study 3 Retrospective Analysis Participants in the Drug Y group had a different mean duration of the overall migraine episode compared to historical non-specific interventions.
  • Conclusion (Study 3): The authors of the analysis suggested a possible link between the study intervention and the time-frame of a migraine event.

Safety Profile Observations

Studies examined the overall reporting of events associated with this combination; however, interactions with other NSAIDs are a factor reported in research. The development of this combination has been described in research as an alternative strategy for addressing pain.

  • Study 4 (Gastric Tolerability): A Phase III study found that GI adverse events (e.g., nausea, dyspepsia) were more frequently reported in the combination group than in the Drug X alone group. The study concluded with an overview of all observed gastrointestinal events.

Frequently Asked Questions (FAQ)

Common questions about Lenazine (FAQ)

Q: How quickly does Lenazine start working?

A: According to the official product information, Lenazine begins to work relatively quickly. Effects are typically reported to be noticeable within 20 minutes after taking the medicine by mouth, and within 5 minutes if administered by intravenous injection.


Q: Does Lenazine cause weight gain or loss?

A: Weight changes, such as weight gain or loss, are not listed as frequent or serious adverse reactions in the official regulatory labeling for Lenazine. The focus of the safety warnings remains on central nervous system and hematologic effects.


Q: Do you need a prescription to get Lenazine?

A: Yes. Lenazine (Promethazine hydrochloride) is classified as a prescription-only medicine (Rx) by regulatory bodies. As a prescription-only medicine (Rx), Lenazine requires a valid prescription for dispensing.


Q: What happens if I miss a dose of Lenazine?

A: Regulatory documents offer specific instructions for managing a missed dose, which patients are typically advised to review in their medication guide. The key regulatory safety caution states that a person should never take a double dose to compensate for a missed dose.


Q: Is it normal to feel dizzy when starting Lenazine?

A: Yes, dizziness is listed in the official product labeling as one of the commonly reported side effects of Lenazine. This sensation is often most apparent when treatment is initiated, as the body adjusts to the drug’s effects on the central nervous system.


Q: What foods should I avoid when taking Lenazine?

A: The official product information does not mandate the strict avoidance of specific foods while taking Lenazine. Taking the oral forms with food, water, or milk may even be suggested, as this can help minimize potential stomach irritation.


Q: Are there any long-term effects of taking Lenazine?

A: Official labeling does not provide a single statement on the overall long-term safety profile. However, regulatory warnings note the potential for certain rare but serious blood disorders, such as leukopenia and agranulocytosis, which have been reported with use.


Q: Has Lenazine been studied in children?

A: Yes. Lenazine is officially contraindicated (prohibited) for use in children younger than two years of age due to the risk of respiratory depression. Dosing parameters have been established for pediatric patients aged two years and older, with the amount determined based on the child’s weight.


Q: Does Lenazine affect sleep patterns?

A: Lenazine is known to have significant sedative properties and is used clinically to promote sleep or quiet restfulness. The regulatory label lists both drowsiness and, in some cases, nightmares as potential side effects.


Q: Can Lenazine cause mood changes or irritability?

A: Official adverse reaction reports mention effects on the nervous system, including feelings such as nervousness, restlessness, and disorientation. Excitement and irritability are also reported, particularly in some children.


Q: Are there generic versions of Lenazine available?

A: Yes. The active ingredient in Lenazine, Promethazine hydrochloride, is available in various generic formulations from different manufacturers, which is standard for many prescription medicines.


Q: Do I need to take Lenazine with food?

A: Official guidance indicates that oral forms of Lenazine can be taken with food, water, or milk. The primary purpose of this recommendation is to help lessen potential stomach irritation or discomfort.


Q: Can women who are planning to conceive take Lenazine?

A: Regulatory documents state that use during pregnancy is generally not recommended or should be avoided, as components of the medicine can pass to the fetus. Official information advises reviewing treatment options with a healthcare provider if conception is planned.


Q: Is Lenazine an antidepressant or an anti-anxiety drug?

A: Lenazine is primarily classified as a first-generation antihistamine with strong antiemetic (anti-nausea) properties. Official documents do not classify it as an antidepressant or a primary anti-anxiety medicine, though its sedative action can affect the central nervous system.


Q: Is it possible to develop a tolerance to Lenazine?

A: The official product information indicates that tolerance may develop to the sedative effects of the medicine over time. This suggests that the initial drowsiness experienced might become less pronounced with continued use.


Q: Why do some people need to adjust their dose of Lenazine?

A: Dose adjustments may be necessary to find the smallest effective amount to relieve symptoms. Dosage can also be adjusted based on individual factors such as the patient’s age, weight, and the severity of the condition being treated, as noted in the administration guidelines.


Q: What is the 'half-life' of Lenazine?

A: The plasma elimination half-life is a measure of the time it takes for half of the drug to be cleared from the bloodstream. For Lenazine (Promethazine), the half-life is officially reported to range approximately from 9 to 16 hours.


Q: Can I take other mental health medications while on Lenazine?

A: Caution is advised when Lenazine is taken alongside other medications that affect the central nervous system. Regulatory warnings indicate that combining these drugs may significantly increase, prolong, and intensify the sedative effects and potential physical impairment caused by Lenazine.


Q: What are the official guidelines for the use of Lenazine?

A: Official regulatory guidelines authorize the use of Lenazine across a set of indications including symptomatic relief of allergic conditions, promoting sedation, and managing nausea, vomiting, and motion sickness.


Q: Can I still consume alcohol in moderation while on Lenazine?

A: Official regulatory labeling advises against the use of alcohol while taking Lenazine. Alcohol is a CNS depressant which, when combined with Lenazine, can significantly increase and intensify both the sedative effects and physical impairment.

How should Lenazine be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing Lenazine (Promethazine hydrochloride) to maintain product stability and ensure safety.

Storage Conditions

The medicine must be stored at Controlled Room Temperature, defined as 20° to 25°C (68° to 77°F). Brief temperature excursions are permitted between 15° to 30°C (59° to 86°F). Lenazine must be protected from light and should not be frozen. The product must be kept in a tight, light-resistant container and the container must remain tightly closed.

Safety and Disposal

It is required to keep this and all drugs out of the reach of children. For unused or expired medicine, the preferred disposal method is taking the product to an authorized drug take-back location. If a take-back program is unavailable, the product should be mixed with an unappealing substance (like dirt or litter) and sealed in a bag for disposal in the household trash, following FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lenazine found in:

A-Z Index: